{"title":"The Current Treatments Of Pulmonary Arterial Hypertension","authors":"G. Butrous","doi":"10.26577/IAM.2020.V1.I1.02","DOIUrl":null,"url":null,"abstract":"Pulmonary hypertension is a debilitating chronic disease. In the last 20 years, there has been impressive progress in the treatment strategy of pulmonary arterial hypertension. This led to a significant increase in the awareness and improvement in the clinical outcome, though there was no substantial improvement in the rate of mortality. This review summarizes the current state of the art of the treatment of pulmonary arterial hypertension, including the three main categories of pulmonary hypertension specific medication which were introduced in the last 20 years. Mainly drugs that restore prostaglandins function of the endothelial cells, drugs that restore Cyclic GMP in the endothelial cells and various forms of medication that inhibit Endothelin receptors. The current strategy to treat patients with pulmonary arterial hypertension is to initiate drug therapy as early as possible and to adopt combinational therapy using two or more classes of drugs simultaneously. There are current efforts to introduce future medication that can be more specific to a phenotype of pulmonary hypertension.","PeriodicalId":34543,"journal":{"name":"Interdisciplinary Approaches to Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interdisciplinary Approaches to Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26577/IAM.2020.V1.I1.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Pulmonary hypertension is a debilitating chronic disease. In the last 20 years, there has been impressive progress in the treatment strategy of pulmonary arterial hypertension. This led to a significant increase in the awareness and improvement in the clinical outcome, though there was no substantial improvement in the rate of mortality. This review summarizes the current state of the art of the treatment of pulmonary arterial hypertension, including the three main categories of pulmonary hypertension specific medication which were introduced in the last 20 years. Mainly drugs that restore prostaglandins function of the endothelial cells, drugs that restore Cyclic GMP in the endothelial cells and various forms of medication that inhibit Endothelin receptors. The current strategy to treat patients with pulmonary arterial hypertension is to initiate drug therapy as early as possible and to adopt combinational therapy using two or more classes of drugs simultaneously. There are current efforts to introduce future medication that can be more specific to a phenotype of pulmonary hypertension.